Iovance Biotherapeutics (IOVA) Competitors $2.19 -0.08 (-3.52%) Closing price 04:00 PM EasternExtended Trading$2.21 +0.02 (+0.91%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. AMRX, NAMS, XENE, CGON, RARE, VKTX, KNSA, APLS, MOR, and GMTXShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include AMNEAL PHARMACEUTICALS (AMRX), NewAmsterdam Pharma (NAMS), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), Ultragenyx Pharmaceutical (RARE), Viking Therapeutics (VKTX), Kiniksa Pharmaceuticals International (KNSA), Apellis Pharmaceuticals (APLS), MorphoSys (MOR), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Its Competitors AMNEAL PHARMACEUTICALS NewAmsterdam Pharma Xenon Pharmaceuticals CG Oncology Ultragenyx Pharmaceutical Viking Therapeutics Kiniksa Pharmaceuticals International Apellis Pharmaceuticals MorphoSys Gemini Therapeutics Amneal Pharmaceuticals (NASDAQ:AMRX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Which has more risk & volatility, AMRX or IOVA? Amneal Pharmaceuticals has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Do institutionals & insiders hold more shares of AMRX or IOVA? 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to AMRX or IOVA? In the previous week, Iovance Biotherapeutics had 4 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 9 mentions for Iovance Biotherapeutics and 5 mentions for Amneal Pharmaceuticals. Iovance Biotherapeutics' average media sentiment score of 0.54 beat Amneal Pharmaceuticals' score of 0.37 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iovance Biotherapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AMRX or IOVA more profitable? Amneal Pharmaceuticals has a net margin of 0.12% compared to Iovance Biotherapeutics' net margin of -161.44%. Iovance Biotherapeutics' return on equity of -52.87% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals0.12% -189.49% 6.17% Iovance Biotherapeutics -161.44%-52.87%-41.31% Which has preferable valuation and earnings, AMRX or IOVA? Amneal Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.85B1.13-$116.89M$0.011,029.00Iovance Biotherapeutics$241.53M3.28-$372.18M-$1.23-1.78 Do analysts prefer AMRX or IOVA? Amneal Pharmaceuticals currently has a consensus target price of $12.00, suggesting a potential upside of 16.62%. Iovance Biotherapeutics has a consensus target price of $11.90, suggesting a potential upside of 443.38%. Given Iovance Biotherapeutics' higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Iovance Biotherapeutics 2 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.27 SummaryAmneal Pharmaceuticals beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$821.41M$3.37B$6.14B$10.65BDividend YieldN/A2.29%5.66%4.70%P/E Ratio-1.7821.3485.8427.65Price / Sales3.28470.58621.60138.35Price / CashN/A47.1938.3262.20Price / Book0.9410.4313.066.79Net Income-$372.18M-$52.40M$3.30B$275.88M7 Day Performance-2.67%6.36%4.81%2.64%1 Month Performance-7.59%16.14%9.99%9.13%1 Year Performance-77.21%33.90%85.28%35.89% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.5554 of 5 stars$2.19-3.5%$11.90+443.4%-76.6%$821.41M$241.53M-1.78500News CoverageAnalyst ForecastAMRXAMNEAL PHARMACEUTICALS2.8651 of 5 stars$9.87+1.2%$12.00+21.6%+21.0%$3.10B$2.79B987.998,100Analyst ForecastNAMSNewAmsterdam Pharma3.1125 of 5 stars$27.52-3.4%$42.00+52.6%+85.2%$3.10B$45.56M-16.994Analyst ForecastXENEXenon Pharmaceuticals2.8656 of 5 stars$39.06+2.8%$53.30+36.5%-4.3%$3.01B$9.43M-11.00210News CoverageAnalyst ForecastAnalyst RevisionCGONCG Oncology2.1965 of 5 stars$39.08+4.1%$56.55+44.7%+16.9%$2.98B$1.14M-22.0861News CoverageAnalyst ForecastRAREUltragenyx Pharmaceutical4.3816 of 5 stars$30.36+4.4%$81.50+168.4%-42.1%$2.93B$560.23M-5.491,294Analyst ForecastVKTXViking Therapeutics3.9837 of 5 stars$25.81+0.9%$86.42+234.8%-51.5%$2.90BN/A-16.8720Analyst ForecastGap UpKNSAKiniksa Pharmaceuticals International3.6726 of 5 stars$38.77+6.2%$44.29+14.2%+56.6%$2.87B$423.24M969.49220News CoverageAnalyst DowngradeAPLSApellis Pharmaceuticals4.0876 of 5 stars$22.65+1.3%$33.29+47.0%-9.1%$2.86B$781.37M-12.44770Analyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$65.55+4.9%N/A+43.4%$2.84BN/A-65.5530 Related Companies and Tools Related Companies AMNEAL PHARMACEUTICALS Competitors NewAmsterdam Pharma Competitors Xenon Pharmaceuticals Competitors CG Oncology Competitors Ultragenyx Pharmaceutical Competitors Viking Therapeutics Competitors Kiniksa Pharmaceuticals International Competitors Apellis Pharmaceuticals Competitors MorphoSys Competitors Gemini Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
